依那西普治疗强直性脊柱炎的疗效分析

目的 评价依那西普治疗强直性脊柱炎的效果和安全性。方法 86例强直性脊柱炎患者随机分为试验组和对照组（n=43）。试验组予以非甾体类抗炎药(NSAIDs)和依那西普（25 mg，2次/周，上臂皮下注射）治疗;对照组予以NSAIDs和柳氮磺吡啶治疗。患者于治疗3个月后复查，分析腰痛发生率、腰部晨僵时间、Bath 强直性脊柱炎疾病活动指数（BASDAI）、Bath 强直性脊柱炎功能指数（BASFI）、红细胞沉降率（ESR）和C反应蛋白（CRP）的变化，观察有无不良反应。结果 与入组时比较，两组患者治疗3个月后腰痛发生率明显降低（P<0.05或P<0.01），腰部晨僵时间明显缩短（P<0.05），BASDAI和BASFI评分显著改善（P<0.05），ESR和CRP明显降低（P<0.05）。治疗3个月后，试验组各项临床指标改善程度均明显优于对照组（P<0.05）;两组患者不良反应发生率比较，差异无统计学意义(P>0.05)。结论 依那西普治疗强直性脊柱炎的短期疗效显著，且不良反应轻微。

Efficacy of etanercept on ankylosing spondylitis

Objective To evaluate the efficacy and safety of etanercept in treatment of ankylosing spondylitis. MethodsEighty-six patients were randomized into experiment group and control group (n=43). Patients in experiment group were treated with non-steroidal antiinflammatory drugs (NSAIDs) and etanercept (25 mg, twice/week, subcutaneous injection in the upper arm), and those in control group were managed with NSAIDs and sulfasalazine. Reexaminations were performed after treatment for 3 months, and the prevalence of low back pain, time of morning stiffness, Bath ankylosing spondylitis disease activity index(BASDAI), Bath ankylosing spondylitis functional index(BASFI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were analysed, and the prevalence of adverse effects was observed. ResultsCompared with those at administration, the prevalences of low back pain significantly reduced (P<0.05 or P<0.01), the time of morning stiffness significantly decreased (P<0.05), BASDAI and BASFI significantly improved, and ESR and CRP significantly decreased 3 months after treatment in both groups (P<0.05). After treatment for three months, the clinical parameters in experiment group were more favourable than those in control group (P<0.05). There was no significant difference in the prevalence of adverse effects between two groups (P>0.05). Conclusion Etanercept has favourable short-term therapeutic effects on ankylosing spondylitis with minor adverse effects.